Technology ID
TAB-5068

T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies

E-Numbers
E-010-2024-0
Lead Inventor
Allen, Clint
Lead IC
NCI
Co-Inventors
Norberg, Scott
ICs
NCI
Applications
Research Materials
Therapeutic Areas
Oncology
Infectious Disease
Immunology
Development Stages
Pre-clinical (in vivo)

Summary:

The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6  in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma.

Description of Technology:

Chronic infections with low-risk HPV types 6 and 11 can lead to such diseases as recurrent respiratory papillomatosis and anogenital condyloma. Such diseases can lower quality of life considerably, expose patients to repeated invasive procedures (such as surgery) and are often recurrent and unresponsive to standard treatments. There are few targeted treatments in development against these diseases. Therefore, there may be a need for reliable research tools to test the potency of targeted treatments, particularly immunotherapies, prior to the product’s release for patient use.


The researchers at the National Cancer Institute (NCI) identified a novel T cell receptor (TCR) specific for an antigen derived from HPV6 E2, restricted to HLA-B55. This TCR was reconstructed with a mouse constant region for tracking in donor T cells and may be used in potency testing and release assays of vaccines and other immunotherapies that target HPV6.

The NCI seeks licensees for the research-use TCR and the panel of Cos7 cells. This invention offers a unique opportunity for developing new TCR-based therapies and validation tools for HPV-related diseases.

Potential Commercial Applications:  

  • Research materials to support therapeutic or diagnostic development against HPV-related diseases
  • Potency testing and other release assays of HPV 6-containing immunotherapy products

Competitive Advantages:

  • Unique TCR and cell line panel to validate T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma
  • Superior tools – together or separately – in release assays for HPV 6-targeting immunotherapy products
  • Unique tools for lot release assays for low- or high-risk HPV-targeting immunotherapy products
  • Unique tools for lot release, stability and comparability studies

Request More Info

Licensing Contact:
Sherwani, Zehra
zehra.sherwani@nih.gov

Publications

  • Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144.

Collaborations

  • Licensing

Collaboration Description

  • Researchers at the NCI seek licensing for this invention that comprises a novel T cell receptor (TCR) targeting HPV6 E2 in the context of HLA-B55 and a panel of Cos7 cells expressing different Class I human leukocyte antigen (HLA) proteins, that may be used in development of validation and potency assays for vaccines and other therapies designed to induce HPV6-specific T cell responses.
Date Published